Want to see IN:LAURUSLABS full AI Analyst Report?
LAURUSLABS Stock Chart & Stats
₹1602.30
₹112.20(7.01%)
At close: 4:00 PM EDT
₹1602.30
₹112.20(7.01%)
Day’s Range― - ―
52-Week Range₹810.75 - ₹1,826.00
Previous CloseN/A
Volume7.99M
Average Volume (3M)107.31K
Market Cap
₹981.15B
Enterprise Value₹560.82K
Total Cash (Recent Filing)₹1.14B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)89.7
Beta0.97
Next Earnings
Oct 22, 2026EPS Estimate
5.58Next Dividend Ex-DateN/A
Dividend Yield0.11%
Share Statistics
EPS (TTM)20.25
Shares Outstanding540,249,600
10 Day Avg. Volume186,027
30 Day Avg. Volume107,314
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)10.11
Price to Sales (P/S)7.86
P/FCF Ratio137.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,430.00Price Target Upside-10.75% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)24.69
Revenue Forecast (FY)₹82.93B
Bulls Say, Bears Say
Bulls Say
Diverse Pharma Revenue Streams (APIs, Formulations, CDMO)Multiple durable revenue pillars—API sales, finished formulations and CDMO services—reduce reliance on any single product or customer. Long-term contracts, recurring manufacturing work and service fees create predictable revenue mix and support resilience through product cycles and geographic diversification.
Improving Profitability And LeverageSustained margin recovery and a declining debt-to-equity ratio signal improving operational efficiency and capital structure. Over a multi-quarter horizon this strengthens the company's ability to invest, absorb shocks, and pursue CDMO contracts that require capital and balance-sheet stability.
Regulated-market Manufacturing And Compliance CapabilitiesCompliant manufacturing for regulated markets and established CDMO capabilities create high entry barriers and stickier customer relationships. These structural advantages enable consistent contract wins, premium service positioning and steady demand from customers constrained by regulatory quality needs.
Bears Say
Weak And Volatile Free Cash FlowPersistent weak FCF despite earnings recovery indicates heavy capex or working-capital absorption. Over months this constrains reinvestment, debt repayment and ability to fund CDMO scale-ups internally, increasing reliance on external financing when opportunistic investments or volatility arise.
Gross Margin Compression And Choppy Top-lineA sustained drop in gross margin suggests structural cost or pricing pressures and product-mix changes that can erode long-term profitability. Combined with uneven revenue trends, this raises uncertainty around the durability of margin recovery and sustainable cash generation over the coming quarters.
Meaningful Absolute Debt And Sensitivity To Cash FlowAlthough leverage ratios improved, significant absolute debt makes the company sensitive to any cash-flow hiccups. Over a 2–6 month horizon this can limit strategic flexibility, raise refinancing or covenant risks, and constrain appetite for incremental capex or M&A if cash conversion weakens further.
Laurus Labs Ltd. News
LAURUSLABS FAQ
What was Laurus Labs Ltd.’s price range in the past 12 months?
Laurus Labs Ltd. lowest stock price was ₹810.75 and its highest was ₹1826.00 in the past 12 months.
What is Laurus Labs Ltd.’s market cap?
Laurus Labs Ltd.’s market cap is ₹981.15B.
When is Laurus Labs Ltd.’s upcoming earnings report date?
Laurus Labs Ltd.’s upcoming earnings report date is Oct 22, 2026 which is in 81 days.
How were Laurus Labs Ltd.’s earnings last quarter?
Laurus Labs Ltd. released its earnings results on Jul 24, 2026. The company reported ₹6.8 earnings per share for the quarter, beating the consensus estimate of ₹4.912 by ₹1.888.
Is Laurus Labs Ltd. overvalued?
According to Wall Street analysts Laurus Labs Ltd.’s price is currently Overvalued.
Does Laurus Labs Ltd. pay dividends?
Laurus Labs Ltd. pays a Semiannually dividend of ₹1.2 which represents an annual dividend yield of 0.11%. See more information on Laurus Labs Ltd. dividends here
What is Laurus Labs Ltd.’s EPS estimate?
Laurus Labs Ltd.’s EPS estimate is 5.58.
How many shares outstanding does Laurus Labs Ltd. have?
Laurus Labs Ltd. has 540,249,600 shares outstanding.
What happened to Laurus Labs Ltd.’s price movement after its last earnings report?
Laurus Labs Ltd. reported an EPS of ₹6.8 in its last earnings report, beating expectations of ₹4.912. Following the earnings report the stock price went up 2.168%.
Which hedge fund is a major shareholder of Laurus Labs Ltd.?
Currently, no hedge funds are holding shares in IN:LAURUSLABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Laurus Labs Ltd.
Established in 2005 and headquartered in Hyderabad, India, Laurus Labs Limited, along with its subsidiaries, operates as a diversified global pharmaceutical company. It focuses on the research, manufacturing, and international distribution of a broad spectrum of medicines and active pharmaceutical ingredients (APIs). The company's API and advanced intermediate offerings cover key therapeutic domains such as anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C. Additionally, Laurus Labs develops and produces oral solid dosage forms targeting ARV, antidiabetic, cardiovascular, PPI, and central nervous system (CNS) conditions. Beyond its proprietary products, the firm extends its expertise through contract development and manufacturing services for other pharmaceutical enterprises. It also supplies specialized ingredients vital for nutraceutical, dietary supplement, and cosmeceutical applications. Furthermore, Laurus Labs is at the forefront of innovation, engineering novel enzymatic solutions for industrial biotechnology, and providing animal-origin-free recombinant proteins and enzymes for biopharmaceutical use, alongside offering a range of business support services within the pharmaceutical industry.
LAURUSLABS Stock 12 Month Forecast
Average Price Target
₹1,430.00
▼(-10.75% Downside)
Technical Analysis
Aurobindo Pharma Ltd
―
Divi's Laboratories Limited
―
Dr. Reddy's Laboratories Ltd.
―
Lupin Limited
―
Sun Pharmaceutical Industries Limited
―







